FREMONT, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) announced today that the Form S-3 Registration
Statement filed in connection with the 2.00% Convertible Senior Notes due 2012
in an aggregate amount of $250.0 million has been declared effective by the
U.S. Securities and Exchange Commission. The offering was completed in
February 2005 pursuant to Rule 144A under the Securities Act of 1933, as
amended.
PDL is a biopharmaceutical company focused on the research, development
and commercialization of novel therapies for inflammation and autoimmune
diseases, acute cardiac conditions and cancer. PDL markets several
biopharmaceutical products in the United States through its hospital sales
force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the
development of humanized antibodies, PDL has licensed its patents to numerous
pharmaceutical and biotechnology companies, some of which are now paying
royalties on net sales of licensed products. Further information on PDL is
available at http://www.pdl.com.
Protein Design Labs and the PDL logo are registered U.S. trademarks of
Protein Design Labs, Inc.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Senior Director, Corporate
Communications
|
